ArticleJCO oncology practice2020
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
Article in JCO oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Time From Screening to Treatment at Accredited Breast Centers in the United States.JCO oncology practice · 2025Article
- Did the COVID-19 consortium recommendations impact the treatment of breast cancer during the COVID-19 pandemic?Breast cancer research and treatment · 2025Article
- Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.Cancers · 2024Review
- Impact of in vitro SARS-CoV-2 infection on breast cancer cells.Scientific reports · 2024Article
- Breast cancer incidence, stage distribution, and treatment shifts during the 2020 COVID-19 pandemic: a nationwide population-level study.Archives of public health = Archives belges de sante publique · 2024Article
- Impact of COVID-19 on patients with metastatic breast cancer: REthink Access to Care and Treatment survey results.Future oncology (London, England) · 2024Article
- Impact of the Coronavirus disease pandemic on early breast cancer.Frontiers in oncology · 2024Article
- Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App.JCO oncology practice · 2023Article
- Therapy delay due to COVID-19 pandemic among European women with breast cancer: prevalence and associated factors.Journal of cancer research and clinical oncology · 2023Article
- COVID-19 and Breast Cancer: Analysis of Surgical Management of a Large Referral Center during the 2020-2021 Pandemic Period.Current oncology (Toronto, Ont.) · 2023Article
- Impact of COVID-19 on Breast Cancer Management in a Multiethnic Middle-Income Asian Country Setting.European journal of breast health · 2023Article
- A Qualitative Study of the Impact of the COVID-19 Pandemic on Metastatic Breast Cancer Care.Journal of patient experience · 2023Article
- Factors associated with the time to treat breast cancer in the pandemic period: an observational study.Revista brasileira de enfermagem · 2023Observational
- Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy.Therapeutic advances in medical oncology · 2023Review
- The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres.European journal of cancer (Oxford, England : 1990) · 2022Article
- Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.Breast (Edinburgh, Scotland) · 2022Review
- Cancer Patients First Treated with Chemotherapy: Are They More Likely to Receive Surgery in the Pandemic?Current oncology (Toronto, Ont.) · 2022Article
- Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.JAMA network open · 2022Article
- Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population.Breast cancer research and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
Abstract
The COVID-19 pandemic has rapidly changed delivery of cancer care. Many nonurgent surgeries are delayed to preserve hospital resources, and patient visits to health care settings are limited to reduce exposure to SARS-CoV-2. Providers must carefully weigh risks and benefits of delivering immunosuppressive therapy during the pandemic. For breast cancer, a key difference is increased use of neoadjuvant systemic therapy due to deferral of many breast surgeries during the pandemic. In some cases, this necessitates increased use of genomic tumor profiling on core biopsy specimens to guide neoadjuvant therapy decisions. Breast cancer treatment during the pandemic requires multidisciplinary input and varies according to stage, tumor biology, comorbidities, age, patient preferences, and available hospital resources. We present here the Johns Hopkins Women's Malignancies Program approach to breast cancer management during the COVID-19 pandemic. We include algorithms based on tumor biology and extent of disease that guide management decisions during the pandemic. These algorithms emphasize medical oncology treatment decisions and demonstrate how we have operationalized the general treatment recommendations during the pandemic proposed by national groups, such as the COVID-19 Pandemic Breast Cancer Consortium. Our recommendations can be adapted by other institutions and medical oncology practices in accordance with local conditions and resources. Guidelines such as these will be important as we continue to balance treatment of breast cancer against risk of SARS-CoV-2 exposure and infection until approval of a vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.